LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Kodu・Aktsiate loetelu・Editas Medicine Inc

Editas Medicine Inc

Suletud

SektorTervishoid

2.19 7.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.01

Max

2.27

Põhinäitajad
By Trading Economics
Sissetulek	28M -25M
Müük	4M 7.5M
Kasumimarginaal	-332.984
Töötajad	246
EBITDA	27M -22M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	+86.05% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-65M 210M
Eelmine avamishind	-5.16
Eelmine sulgemishind	2.19

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.33 / 1.54 Toetus ja vastupanu

Editas Medicine Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. märts 2026, 23:39 UTC

Kuumad aktsiad

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4. märts 2026, 23:20 UTC

Tulu

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4. märts 2026, 21:43 UTC

Tulu

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4. märts 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

4. märts 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4. märts 2026, 23:24 UTC

Market Talk

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4. märts 2026, 22:30 UTC

Tulu

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4. märts 2026, 22:13 UTC

Tulu

Vermilion Energy 4Q EPS C$2.86 >VET

4. märts 2026, 22:04 UTC

Market Talk

RBA Slipping Behind The Curve On Rates -- Market Talk

4. märts 2026, 21:53 UTC

Tulu

Lithium Americas 4Q Rev $66.8M >LAC

4. märts 2026, 21:53 UTC

Tulu

Lithium Americas 4Q Loss/Shr 52c >LAC

4. märts 2026, 21:52 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:50 UTC

Tulu

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4. märts 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4. märts 2026, 21:48 UTC

Tulu

Webull 4Q Rev $165.2M >BULL

4. märts 2026, 21:48 UTC

Tulu

Webull 4Q EPS 1c >BULL

4. märts 2026, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. märts 2026, 21:45 UTC

Market Talk

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4. märts 2026, 21:40 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:36 UTC

Uudisväärsed sündmused

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4. märts 2026, 21:27 UTC

Tulu

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4. märts 2026, 21:17 UTC

Market Talk

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4. märts 2026, 21:16 UTC

Tulu

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q EPS $1.50 >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q Net $7.35B >AVGO

4. märts 2026, 21:15 UTC

Tulu

Broadcom 1Q Rev $19.31B >AVGO

Võrdlus sarnastega

Hinnamuutus

Editas Medicine Inc Prognoos

Hinnasiht

By TipRanks

86.05% tõus

12 kuu keskmine prognoos

Keskmine 4 USD 86.05%

Kõrge 4 USD

Madal 4 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Editas Medicine Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Editas Medicine Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.33 / 1.54Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.